MedTrace Logo

Paliperidone Palmitate Flexible Dosing in Schizophrenia

NCT01281527 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1044

Last updated 2014-03-10

No results posted yet for this study

Summary

This study explores the tolerability, safety and efficacy (i.e. how well the drug works) of flexibly dosed paliperidone palmitate in the treatment of schizophrenia in patients previously unsuccessfully treated with other oral or long-acting injectable (LAI) (i.e. with a long duration of action) antipsychotics.

Conditions

Interventions

DRUG

Paliperidone Palmitate

50 - 150 mg eq. every 30 days

Sponsors & Collaborators

  • Janssen-Cilag International NV

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag International NV Clinical Trial · Janssen-Cilag International NV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-11-30
Completion
2013-11-30

Countries

  • Austria
  • Belgium
  • Croatia
  • Denmark
  • Estonia
  • France
  • Germany
  • Greece
  • Hungary
  • Israel
  • Latvia
  • Lithuania
  • Netherlands
  • Portugal
  • Spain
  • Sweden
  • Switzerland
  • Turkey (Türkiye)
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01281527 on ClinicalTrials.gov